Skip to main content

Table 2 Univariable and multivariable analyses of recurrence-free survival of patients with EGFR-Mt lung cancer

From: Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status

Recurrent-fee survival
Variable
Univariable analysis Multivariable analysis
HR 95% CI p value HR 95% CI p value
Age (≥65) 0.95 0.64–1.44 0.829    
Gender (Male) 1.21 0.82–1.81 0.333    
Smoking history (+) 1.43 0.96–2.12 0.079 1.49 1.00–2.22 0.049
Side (left) 1.48 0.99–2.23 0.058 1.36 0.90–2.06 0.139
CEA (> 10 ng/ml) 1.85 1.14–3.00 0.013 1.29 0.77–2.14 0.334
CT tumor size (> 4.0 cm) 1.31 0.85–2.02 0.224    
Consolidation size (> 4.0 cm) 1.43 0.90–2.27 0.127    
GGO (−) 1.48 0.98–2.24 0.066 1.24 0.80–1.92 0.337
PET maxSUV (≥6.0) 2.21 1.48–3.28 < 0.001 1.37 0.88–2.12 0.161
Surgical procedure (segmentectomy) 0.46 0.11–1.88 0.282    
Invasive lepidic adenocarcinoma 0.61 0.30–1.26 0.182    
Invasive acinar adenocarcinoma 0.78 0.52–1.17 0.225    
Invasive papillary adenocarcinoma 1.29 0.85–1.95 0.225    
Invasive solid adenocarcinoma 1.64 0.83–3.27 0.156    
Invasive micropapillary adenocarcinoma 1.18 0.52–2.71 0.690    
High grade adenocarcinoma 1.54 0.91–2.61 0.104    
Lymphatic vessel invasion (+) 2.02 1.36–3.00 < 0.001 1.25 0.81–1.93 0.308
Blood vessel invasion (+) 2.96 1.86–4.73 < 0.001 1.84 1.09–3.12 0.023
Pleural invasion (+) 1.10 0.73–1.66 0.645    
Nodal metastasis (+) 2.71 1.77–4.14 < 0.001 1.96 1.23–3.12 0.005
Lepidic component (+) 1.05 0.56–1.97 0.877    
Solid component (+) 1.02 0.69–1.52 0.916    
Micropapillary component (+) 1.34 0.89–2.03 0.161    
Adjuvant chemotherapy (%) 1.02 0.69–1.53 0.906    
EGFR exon 21L858R 1.01 0.68–1.50 0.962    
  1. CT Computed tomography, GGO Ground glass opacity, PET Positron emission tomography, SUV Standardized uptake value, EGFR Epidermal growth factor receptor, HR Hazards ratio, CI Confidence interval